TherOx, Inc. Completes Acquisition By ZOLL Medical Corporation
Represented TherOx, Inc. in its acquisition by ZOLL Medical Corporation, an Asahi Kasei Group Company that develops and markets medical devices and software solutions. Financial terms of this transaction were not disclosed. TherOX, Inc. is a privately held company focused on improving treatment of acute myocardial infarction and markets systems to deliver SuperSaturated Oxygen Therapy (SSO2).
SSO2 Therapy can help reduce infarct size among patients who suffer from large anterior AMIs, which are the most serious heart attacks,” said Kevin T. Larkin, President and Chief Executive Officer of TherOx. “Adjunctive to PCI, SSO2 Therapy is intended to salvage heart muscle and reduce infarct size.
